iMAPS Capital Markets

  • Land: Kaimaninseln

Nachricht vom 11.07.2019 | 15:10

iMAPS Capital Markets: ETF price war is now spilling over into the structured investment products market

DGAP-Media / 11.07.2019 / 15:10

The wealth & asset management industry has been under pressure for years. ETFs, in particular, are exposed to a price war which, as a "race to zero", is receiving widespread media attention. However, asset managers who want to launch investment products on the market to implement their own strategy through a private label structure have not benefited from this price war so far.

Exchange Traded Instruments at a Flat Fee

iMaps Capital Markets, an international private label provider of exchange-traded, actively managed certificates, is bringing this price war to the world of structured investment products with its latest product launch: 0.00% volume-based administration fees!

Asset managers wishing to launch an actively managed structured investment product on their own investment strategy can now order this at a flat rate of just 12,000 USD per year from the experts of iMaps Capital Markets, as they announced on their website http: // This flat-fee covers the auditor's fees, listing fees, paying agent's fees, fee of the Independent Directors of the Notes Issuer and the trustee structure to eliminate the credit risk of the Issuer.

"We wanted to bring something completely different and new to the market and have therefore standardized all the components of a structured investment product in order to save time and money," says Andreas Woelfl, founder and Chairman of iMaps Capital Markets. The new Flat Fee ETIs are therefore only offered in combination with a securities account with Interactive Brokers, the longstanding partner of the iMaps Capital Markets team.

"Interactive Brokers offers a wide range of instruments and market access and within this offer can be actively managed without further restriction, be it foreign exchange strategies, volatility strategies or, for example, a deposit of ETFs," iMaps European CEO Guenter Woinar points out.

Asset Managers, thanks to the team of iMaps Capital Markets, now have the ability to launch and promote their own low-cost strategy investment products under their own trade mark

About iMaps ETI solutions

iMaps Capital Markets is an investment firm specializing in the issuance of Exchange Traded Instruments (ETIs) as a private label solution for asset managers. ETIs are legally derivative securities and are traded on the stock exchange - just like ETFs  The credit risk of the issuer got eliminated by a trust solution with collateralization to Intertrust Group.

The iMaps ETI solution issues ETIs on behalf of asset managers and private banks wishing to put their investment strategy on the market in a stock-exchange-traded investment product. All iMaps ETIs are collateralised and issued in the Swiss clearing system with Swiss ISIN and Swiss paying agent.

iMaps Capital Markets
Andreas Woelfl
iMaps Capital Markets Chairman of the Board of Directors

Guenter Woinar
iMaps Europe CEO

End of Media Release

Issuer: iMAPS Capital Markets
Key word(s): Finance

11.07.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Übersicht Indizes

Weitere News

Anleihe im Fokus

„Semper idem Underberg AG: Emission neuer Unternehmensanleihe 2019/2025“

- Emissionsvolumen: bis zu 60 Mio. Euro
- Anleihenumtausch: 23.010. bis 06.11.2019
- Neuzeichnung: 07.11. bis 12.11.2019
- Stückelung / Mindestanlage: 1.000 Euro
- Zinssatz (Kupon):
Liegt in einer Spanne von 4,00 % bis 4,25 % p.a.
- Laufzeit: 6 Jahre
- Zinszahlung: jährlich, jeweils am 18. November (nachträglich), erstmals am 18. November 2020
- Rückzahlungskurs: 100%
- Fälligkeit: 18. November 2025
- Listing: Listing im Freiverkehr (Open Market) der Frankfurter Wertpapierbörse vorgesehen


Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Linde acquires minority stake in ITM Power and agrees joint venture

23. Oktober 2019, 12:00

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

23. Oktober 2019